研究者業績

山本 直樹

ヤマモト ナオキ  (Naoki Yamamoto)

基本情報

所属
藤田医科大学 研究推進本部・産官学連携推進センター 教授(特任教授)
(兼任)研究推進本部・国際再生医療センター 特任教授
(兼任)大学院 医療科学研究科 兼任教授
学位
医学博士(藤田保健衛生大学)

連絡先
naokiyfujita-hu.ac.jp
研究者番号
00267957
J-GLOBAL ID
200901054071171303
researchmap会員ID
6000005815

外部リンク

学歴

 1

論文

 207
  • Kei Ichikawa, Seiji Tokiwa, Yoshiki Tanaka, Hiroto Toda, Yukihito Kato, Yukihiro Sakai, Kazuo Ichikawa, Naoki Yamamoto
    Journal of Clinical Medicine 2025年9月  
  • Kei Ichikawa, Yoshiki Tanaka, Rie Horai, Yu Kato, Kazuo Ichikawa, Naoki Yamamoto
    Medicina 61(8) 1384-1384 2025年7月30日  査読有り最終著者
    Background and Objectives: Posterior chamber phakic implantable contact lenses (Phakic-ICL) are widely used for refractive correction due to their efficacy and safety, including minimal corneal endothelial cell loss. The Collamer-based EVO+ Visian implantable contact lens (ICL), manufactured from Collamer, which is a blend of collagen and hydroxyethyl methacrylate (HEMA), has demonstrated excellent long-term biocompatibility and optical clarity. Recently, hydrophilic acrylic Phakic-ICLs, such as the Implantable Phakic Contact Lens (IPCL), have been introduced. This study investigated the material differences among Phakic-ICLs and their interaction with fibronectin (FN), which has been reported to adhere to intraocular lens (IOL) surfaces following implantation. The aim was to compare Collamer, IPCL, and LENTIS lenses (used as control) in terms of FN distribution and cell adhesion using a small number of explanted Phakic-ICLs. Materials and Methods: Three lens types were analyzed: a Collamer Phakic-ICL (EVO+ Visian ICL), a hydrophilic acrylic IPCL, and a hydrophilic acrylic phakic-IOL (LENTIS). FN distribution and cell adhesion were evaluated across different regions of each lens. An in vitro FN-coating experiment was conducted to assess its effect on cell adhesion. Results: All lenses demonstrated minimal FN deposition and cellular adhesion in the central optical zone. A thin FN film was observed on the haptics of Collamer lenses, while FN adhesion was weaker or absent on IPCL and LENTIS surfaces. Following FN coating, Collamer lenses supported more uniform FN film formation; however, this did not significantly enhance cell adhesion. Conclusions: Collamer, which contains collagen, promotes FN film formation. Although FN film formation was enhanced, the low cell-adhesive properties of HEMA resulted in minimal cell adhesion even with FN presence. This characteristic may contribute to the long-term transparency and biocompatibility observed clinically. In contrast, hydrophilic acrylic materials used in IPCL and LENTIS demonstrated limited FN interaction. These material differences may influence extracellular matrix protein deposition and biocompatibility in clinical settings, warranting further investigation.
  • Yu Kato, Takeshi Inaba, Koudai Shinke, Noriko Hiramatsu, Tetsuhiro Horie, Takuya Sakamoto, Yuko Hata, Eiji Sugihara, Tetsuya Takimoto, Noriaki Nagai, Yasuhito Ishigaki, Hajime Kojima, Osamu Nagano, Naoki Yamamoto, Hideyuki Saya
    Cells 14(3) 215-215 2025年2月2日  査読有り責任著者
    Developmental toxicity testing is essential to identify substances that may harm embryonic development. This study aimed to establish a protocol for evaluating developmental toxicity using human induced pluripotent stem cells (iPSCs) by analyzing cellular activity and gene expression changes. Two ICH S5(R3) positive substances, valproic acid (VPA), which is a substance previously detected as positive by other test methods, and thalidomide (Thalido), were examined during early trichoderm differentiation without fetal bovine serum. RNA-seq analysis identified seven candidate genes, including TP63, associated with altered expression following exposure to VPA or Thalido. These genes were implicated in pathways related to tissue development, cell growth, and molecular interactions. While the assay effectively detected VPA and Thalido, its limitations include testing only soluble substances and focusing on early differentiation stages. Nevertheless, the protocol demonstrates potential for the classification and evaluation of emerging modality drugs based on physical properties such as solubility, polarity, and pH. Integration with AI analysis may enhance its capacity to uncover genetic variations and evaluate previously uncharacterized substances. This study provides a foundation for alternative developmental toxicity testing methods, with further refinements in the culture method expected to improve accuracy and applicability in regulatory toxicology.
  • Hiroko Otake, Tetsushi Yamamoto, Naoki YAMAMOTO, Yosuke Nakazawa, Yoshiki Miyata, Atsushi Taga, HIROSHI SASAKI, Noriaki Nagai
    Medicina 2025年2月  
  • Takuya Sakamoto, Atsushi Fuku, Tetsuhiro Horie, Hironori Kitajima, Yuka Nakamura, Ikuhiro Tanida, Hiroshi Sunami, Hiroaki Hirata, Yoshiyuki Tachi, Yasuo Iida, Sohsuke Yamada, Naoki Yamamoto, Yusuke Shimizu, Yasuhito Ishigaki, Toru Ichiseki, Ayumi Kaneuji, Satoshi Osawa, Norio Kawahara
    Regenerative Therapy 27 408-418 2024年12月  

MISC

 56
  • 門脇玲太, 浅井拓己, 出口粧央里, 大竹裕子, 中澤洋介, 山本直樹, 長井紀章
    日本白内障学会総会・水晶体研究会プログラム・講演抄録集 62nd-49th 2023年  
  • 山本直樹, 山本直樹, 平松範子, 佐々木洋, 近藤征史, 小島肇
    Journal of Toxicological Sciences 46(Supplement) 2021年  
  • 林 卓馬, 山本 直樹, 田島 香里, 長谷川 正樹, 谷口 巧, 藤田 順之, 石村 大輔
    日本整形外科学会雑誌 94(8) S1859-S1859 2020年9月  
  • Tomohide Souma, Tomoyuki Minezawa, Hiroshi Yatsuya, Takuya Okamura, Kumiko Yamatsuta, Sayako Morikawa, Tomoya Horiguchi, Shingo Maeda, Yasuhiro Goto, Masamichi Hayashi, Sumito Isogai, Naoki Yamamoto, Masashi Kondo, Kazuyoshi Imaizumi
    Chest 158(2) 797-807 2020年3月4日  
    BACKGROUND: Infectious complications after endobronchial ultrasound-guided transbronchial biopsy with a guide sheath (EBUS-GS-TBB) are serious in that they may delay or change scheduled subsequent therapy. The aim of this study was to identify risk factors for infection after EBUS-GS-TBB. RESEARCH QUESTION: What are the risk factors for infection after EBUS-GS-TBB? STUDY DESIGN AND METHODS: We retrospectively reviewed the medical records of 1,045 consecutive patients who had undergone EBUS-GS-TBB for peripheral lung lesions between January 2013 and December 2017 at Fujita Health University Hospital. We evaluated the following risk factors for infectious complications after EBUS-GS-TBB: relevant patient characteristics (age and comorbidities), lesion size, CT scan features of target lesion (intratumoral low-density areas [LDAs] and cavitation), stenosis of responsible bronchus observed by bronchoscopy, and laboratory data before EBUS-GS-TBB (WBC count and C-reactive protein concentration). RESULTS: Forty-seven of the study patients developed infectious complications (24 with pneumonia, 14 with intratumoral infection, three with lung abscess, three with pleuritis, and three with empyema), among whom the complication caused a delay in cancer treatment in 13 patients, cancellation of cancer treatment in seven patients, and death in three patients. Multivariate analysis showed that cavitation (P = .007), intratumoral LDAs (P < .001), and stenosis of responsible bronchus observed by bronchoscopy (P < .001) were significantly associated with infectious complications after EBUS-GS-TBB. Prophylactic antibiotics had been administered to 13 patients in the infection group. Propensity matched analysis could not show significant benefit of prophylactic antibiotics in preventing post-EBUS-GS-TBB infections. INTERPRETATION: Cavitation, LDAs for CT scan features of target lesions, and stenosis of responsible bronchus observed by bronchoscopy are risk factors of post-EBUS-GS-TBB infection. In the cohort, prophylactic antibiotics failed to prevent infectious complications.
  • 山本直樹, 平松範子, 久保江理, 佐々木洋
    日本白内障学会誌 32(1) 2020年  

書籍等出版物

 10
  • 山本 直樹 (担当:分担執筆, 範囲:第2章 動物実験代替法における評価モデル 、第3節 不死化ヒト角膜上皮細胞株を用いた眼刺激性試験代替法)
    株式会社 技術情報協会 2018年6月
  • 山本 直樹 (担当:共著, 範囲:細胞培養基盤技術)
    株式会社 じほう 2013年6月
  • 山本 直樹 (担当:分担執筆, 範囲:フルオレセイン漏出試験法(Fluorescein leakage test method; FL試験法))
    株式会社 シーエムシー出版 2013年6月
  • 山本 直樹 (担当:分担執筆, 範囲:アトピー白内障 -その発症に関与する要因とメカニズム-)
    学際企画株式会社 2011年6月
  • 山本 直樹 (担当:分担執筆, 範囲:子どもに多い目の病気 “感染予防の必要性の有無と指導の実際")
    健学社 2008年10月

講演・口頭発表等

 51

担当経験のある科目(授業)

 7

Works(作品等)

 1

共同研究・競争的資金等の研究課題

 23

産業財産権

 4

その他

 3
  • 市販のリプログラミングベクターを用いて、ヒト末梢血単球由来iPS細胞を作製することに成功した。研究成果は、以下のジャーナルで報告している。Isogai S, Yamamoto N et al., Cell Reprogram 20(6), 347-355, 2018. Hiramatsu N, Yamamoto N et al., Med Mol Morphol 53(2), 63-72, 2020. *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで
  • ヒト虹彩由来iPS細胞の作製に成功した。研究成果は、以下のジャーナルで報告している。Yamamoto N et al., Cells 10(4), 743, 2021. *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで
  • 臓器・組織を迅速に固定できる固定液を発明。日本で特許を取得(特許3723204 難浸透性組織迅速固定液)。本特許の技術の一部を利用した商品(組織用迅速固定液 スーパーフィックス KY-500, クラボウ)が販売されている。他にも、本特許技術を用いた無ホルマリン固定液を開発中。 *本研究シーズに関する産学共同研究の問い合わせは藤田医科大学産学連携推進センター(fuji-san@fujita-hu.ac.jp)まで